GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuno-Biological Laboratories Co Ltd (TSE:4570) » Definitions » PEG Ratio

Immuno-Biological Laboratories Co (TSE:4570) PEG Ratio : N/A (As of Dec. 13, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Immuno-Biological Laboratories Co PEG Ratio?

PE Ratio without NRI / 5-Year EBITDA Growth Rate*

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The growth rate we use is the 5-Year EBITDA growth rate. As of today, Immuno-Biological Laboratories Co's PE Ratio without NRI is 24.10. Immuno-Biological Laboratories Co's 5-Year EBITDA growth rate is 0.00%. Therefore, Immuno-Biological Laboratories Co's PEG Ratio for today is N/A.

* The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


The historical rank and industry rank for Immuno-Biological Laboratories Co's PEG Ratio or its related term are showing as below:


During the past 13 years, Immuno-Biological Laboratories Co's highest PEG Ratio was 9999.00. The lowest was 0.00. And the median was 0.00.


TSE:4570's PEG Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.69
* Ranked among companies with meaningful PEG Ratio only.

Peter Lynch thinks a company with a P/E ratio equal to its growth rate is fairly valued.


Immuno-Biological Laboratories Co PEG Ratio Historical Data

The historical data trend for Immuno-Biological Laboratories Co's PEG Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuno-Biological Laboratories Co PEG Ratio Chart

Immuno-Biological Laboratories Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
PEG Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Immuno-Biological Laboratories Co Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
PEG Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Immuno-Biological Laboratories Co's PEG Ratio

For the Biotechnology subindustry, Immuno-Biological Laboratories Co's PEG Ratio, along with its competitors' market caps and PEG Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Immuno-Biological Laboratories Co's PEG Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuno-Biological Laboratories Co's PEG Ratio distribution charts can be found below:

* The bar in red indicates where Immuno-Biological Laboratories Co's PEG Ratio falls into.



Immuno-Biological Laboratories Co PEG Ratio Calculation

PEG Ratio is defined as the PE Ratio without NRI divided by the growth ratio. The ratio we use is the 5-Year EBITDA growth rate.

Immuno-Biological Laboratories Co's PEG Ratio for today is calculated as

PEG Ratio=PE Ratio without NRI/5-Year EBITDA Growth Rate*
=24.104435421699/0.00
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Note: The 5-Year EBITDA Growth Rate is the 5-year average EBITDA per share growth rate. While the denominator is a percentage, we use the whole number as opposed to the decimal form for the calculation. For example, 5% would be shown as 5 as opposed to 0.05. If it's smaller than or equal to 0, then the PEG Ratio is not calculated.


Immuno-Biological Laboratories Co  (TSE:4570) PEG Ratio Explanation

To compare stocks with different growth rates, Peter Lynch invented a ratio called PEG Ratio. PEG Ratio is defined as the P/E ratio divided by the growth ratio. He thinks a company with a P/E ratio equal to its growth rate is fairly valued. Still he said he would rather buy a company growing 20% a year with a P/E of 20, instead of a company growing 10% a year with a P/E of 10.


Immuno-Biological Laboratories Co PEG Ratio Related Terms

Thank you for viewing the detailed overview of Immuno-Biological Laboratories Co's PEG Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Immuno-Biological Laboratories Co Business Description

Traded in Other Exchanges
N/A
Address
1091-1 Naka Aza-Higashida, Gunma, Fujioka, JPN, 375-0005
Immuno-Biological Laboratories Co Ltd focuses on research and development. It researches, develops, manufacture and supplies various immunological research reagents, and customized services. It is engaged in research and development of materials used in diagnostic products and valuable seeds and technology for protein production using transgenic silkworm cocoons, which make it possible to create valuable proteins as well as antibodies. It works on clinical reagents for cancer research. Its research scientists are producing inflammatory cytokines, growth factors & antibodies for use against these cancers.

Immuno-Biological Laboratories Co Headlines

No Headlines